A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications

Mett et al. describe development of GP532, a substantially deimmunized derivative of Toll-like receptor 5 (TLR5) agonist entolimod. GP532 has mutations eliminating key B- and T-cell epitopes and an inflammasome-activating domain yet remains a potent NF-κB activator with biological effects similar to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vadim Mett, Oleg V. Kurnasov, Ivan A. Bespalov, Ivan Molodtsov, Craig M. Brackett, Lyudmila G. Burdelya, Andrei A. Purmal, Anatoli S. Gleiberman, Ilia A. Toshkov, Catherine A. Burkhart, Yakov N. Kogan, Ekaterina L. Andrianova, Andrei V. Gudkov, Andrei L. Osterman
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/bcafc6dab7b74c02bc2aec45e9ac993a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bcafc6dab7b74c02bc2aec45e9ac993a
record_format	dspace
spelling	oai:doaj.org-article:bcafc6dab7b74c02bc2aec45e9ac993a2021-12-02T14:26:12ZA deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications10.1038/s42003-021-01978-62399-3642https://doaj.org/article/bcafc6dab7b74c02bc2aec45e9ac993a2021-04-01T00:00:00Zhttps://doi.org/10.1038/s42003-021-01978-6https://doaj.org/toc/2399-3642Mett et al. describe development of GP532, a substantially deimmunized derivative of Toll-like receptor 5 (TLR5) agonist entolimod. GP532 has mutations eliminating key B- and T-cell epitopes and an inflammasome-activating domain yet remains a potent NF-κB activator with biological effects similar to entolimod. Thus, GP532 is suitable for multi-dose TLR5-targeting therapies and patients with high titers of preexisting flagellin-neutralizing antibodies.Vadim MettOleg V. KurnasovIvan A. BespalovIvan MolodtsovCraig M. BrackettLyudmila G. BurdelyaAndrei A. PurmalAnatoli S. GleibermanIlia A. ToshkovCatherine A. BurkhartYakov N. KoganEkaterina L. AndrianovaAndrei V. GudkovAndrei L. OstermanNature PortfolioarticleBiology (General)QH301-705.5ENCommunications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Biology (General) QH301-705.5
spellingShingle	Biology (General) QH301-705.5 Vadim Mett Oleg V. Kurnasov Ivan A. Bespalov Ivan Molodtsov Craig M. Brackett Lyudmila G. Burdelya Andrei A. Purmal Anatoli S. Gleiberman Ilia A. Toshkov Catherine A. Burkhart Yakov N. Kogan Ekaterina L. Andrianova Andrei V. Gudkov Andrei L. Osterman A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications
description	Mett et al. describe development of GP532, a substantially deimmunized derivative of Toll-like receptor 5 (TLR5) agonist entolimod. GP532 has mutations eliminating key B- and T-cell epitopes and an inflammasome-activating domain yet remains a potent NF-κB activator with biological effects similar to entolimod. Thus, GP532 is suitable for multi-dose TLR5-targeting therapies and patients with high titers of preexisting flagellin-neutralizing antibodies.
format	article
author	Vadim Mett Oleg V. Kurnasov Ivan A. Bespalov Ivan Molodtsov Craig M. Brackett Lyudmila G. Burdelya Andrei A. Purmal Anatoli S. Gleiberman Ilia A. Toshkov Catherine A. Burkhart Yakov N. Kogan Ekaterina L. Andrianova Andrei V. Gudkov Andrei L. Osterman
author_facet	Vadim Mett Oleg V. Kurnasov Ivan A. Bespalov Ivan Molodtsov Craig M. Brackett Lyudmila G. Burdelya Andrei A. Purmal Anatoli S. Gleiberman Ilia A. Toshkov Catherine A. Burkhart Yakov N. Kogan Ekaterina L. Andrianova Andrei V. Gudkov Andrei L. Osterman
author_sort	Vadim Mett
title	A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications
title_short	A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications
title_full	A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications
title_fullStr	A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications
title_full_unstemmed	A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications
title_sort	deimmunized and pharmacologically optimized toll-like receptor 5 agonist for therapeutic applications
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/bcafc6dab7b74c02bc2aec45e9ac993a
work_keys_str_mv	AT vadimmett adeimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT olegvkurnasov adeimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT ivanabespalov adeimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT ivanmolodtsov adeimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT craigmbrackett adeimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT lyudmilagburdelya adeimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT andreiapurmal adeimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT anatolisgleiberman adeimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT iliaatoshkov adeimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT catherineaburkhart adeimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT yakovnkogan adeimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT ekaterinalandrianova adeimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT andreivgudkov adeimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT andreilosterman adeimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT vadimmett deimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT olegvkurnasov deimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT ivanabespalov deimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT ivanmolodtsov deimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT craigmbrackett deimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT lyudmilagburdelya deimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT andreiapurmal deimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT anatolisgleiberman deimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT iliaatoshkov deimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT catherineaburkhart deimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT yakovnkogan deimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT ekaterinalandrianova deimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT andreivgudkov deimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications AT andreilosterman deimmunizedandpharmacologicallyoptimizedtolllikereceptor5agonistfortherapeuticapplications
_version_	1718391392115359744

A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications

Ejemplares similares